scholarly journals Fludrocortisone Acetate

2020 ◽  
Author(s):  
Keyword(s):  
Fludrocortisone Acetate

scholarly journals Hypersensitivity to Fludrocortisone Acetate in a Recipient of Bone Marrow Transplantation

2011 ◽  
Vol 60 (4) ◽  
pp. 557-558 ◽  
Author(s):  
Jun Kato ◽  
Takehiko Mori ◽  
Mariko Kamo ◽  
Akiko Tanikawa ◽  
Osamu Iketani ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Fludrocortisone Acetate

scholarly journals Fludrocortisone Acetate to Treat Neurally Mediated Hypotension in Chronic Fatigue Syndrome

JAMA ◽  
2001 ◽  
Vol 285 (1) ◽  
pp. 52 ◽  
Author(s):  
Peter C. Rowe ◽  
Hugh Calkins ◽  
Karen DeBusk ◽  
Robin McKenzie ◽  
Ravinder Anand ◽  
...  
Keyword(s):  
Chronic Fatigue Syndrome ◽  
Chronic Fatigue ◽  
Fatigue Syndrome ◽  
Neurally Mediated Hypotension ◽  
Fludrocortisone Acetate

scholarly journals Fludrocortisone acetate-responsive hyponatremia observed in old patients after head injury.

1987 ◽  
Vol 76 (6) ◽  
pp. 867-873 ◽  
Author(s):  
Sane ISHIKAWA ◽  
Toshikazu SAITO ◽  
Kenzo KANEKO ◽  
Koji OKADA ◽  
Takeshi KUZUYA
Keyword(s):  
Head Injury ◽  
Old Patients ◽  
Fludrocortisone Acetate

Corticosteroid-induced stimulation of atrial natriuretic peptide in man

1988 ◽  
Vol 118 (2) ◽  
pp. 179-186 ◽  
Author(s):  
Hermann Saxenhofer ◽  
Martin Angst ◽  
Peter Weidmann ◽  
Sidney G. Shaw ◽  
Claudia Ferrier
Keyword(s):  
Oral Administration ◽  
Potential Role ◽  
Plasma Renin ◽  
Urinary Sodium Excretion ◽  
Elevated Plasma ◽  
Glucocorticoid Treatment ◽  
Volume State ◽  
Normal Humans ◽  
Fludrocortisone Acetate ◽  
Stimulation Of

Abstract. Previously, we reported elevated plasma immunoreactive ANP (irANP) levels from the 2nd to the 9th day of administering either prednisone, 50 mg/day, or 9α-fludrocortisone acetate (9αF), 0.6 mg/day, to normal humans. To investigate the course of plasma irANP levels during the first 48 h of corticosteroid adminstration, 9 healthy men (mean age ± sem, 24 ± 1 years) received in randomised sequence A) a 4-h iv infusion of prednisolone sodium tetrahydrophthalate followed by oral administration of prednisone for 2 days; or B) a 4-h infusion of aldosterone followed by oral administration of 9αF for 2 days. Basal supine plasma irANP levels averaged 32 ± 5 ng/l in study A and 30 ± 6 ng/l in study B; they were unchanged or even deceased up to 24 h of glucocorticoid or mineralocorticoid administration, but rose (P < 0.01) to 56 ± 9 and 62 ± 12 ng/l at 48 h, respectively, of the two interventions. During glucocorticoid treatment, blood pressure (BP) and indices of the sodium-fluid volume state were unchanged after 48 h. During 9αF administration, body weight increased (1.1 ± 0.3%, P < 0.001), whereas urinary sodium excretion (63 ±7%, P < 0.001), hematocrit (4.1 ± 1.1%, P < 0.001), and plasma renin activity (38 ± 4%, P < 0.001) decreased. Conclusions: The increase in circulating irANP at 48 h of administration of either a glucocorticoid or a mineralocorticoid demonstrates a distinct but slow response of the ANP system to these corticosteroids in normal humans. ANP may play a potential role in mediating and/or modulating physiological and pathophysiological effects of corticosteroids.

scholarly journals PRIMARY HYPOADRENOCORTICISM IN A DOG

2016 ◽  
Vol 19 (2) ◽  
Author(s):  
Denner Santos dos Anjos ◽  
Veronica Jorge Babo-Terra ◽  
Mariana Isa Poci Palumbo
Keyword(s):  
Previous History ◽  
Clinical Signs ◽  
Sodium Potassium ◽  
Capillary Refill ◽  
Once Daily ◽  
History Of ◽  
Fludrocortisone Acetate ◽  
Loss Of Appetite ◽  
Veterinary Hospital ◽  
Acute Crisis

This report describes the clinical and laboratorial findings as well as the therapeutic protocol performed in a three-year-old mongrel female intact dog, referred to the Veterinary Hospital of FAMEZ/UFMS. The animal had a previous history of recurrent gastrointestinal signs (such as lethargy, vomiting, loss of appetite, melena and abdominal pain), acute crisis episodes, bradycardia, hypotension, hypothermia and increase of capillary refill time, recognized as addisonian crisis due to primary hypoadrenocorticism. Laboratorial findings included anemia, eosinophilia, neutrophilia, lymphocytosis, sodium-potassium ratio of 14,02 mEq/L and prerenal azotemia. Based on that, it was confirmed the diagnosis of primary hypoadrenocorcitism. Thus, it was recommended supplementation therapy with mineralocorticoid (aldosterone) and glucocorticoid (cortisol) corresponding respectively, fludrocortisone acetate of 0.2 mg per kg of BW, by mouth, once daily and prednisone 0.2 mg per kg of BW, by mouth, twice daily until further recommendations. The prognostic was excellent, since the animal significantly improved body condition, andclinical signs disappeared after therapy which lead the sodium-potassium ratio to 35.11 mEq/L. Thus, the clinician must always suspect of primary hypoadrenocorticism in dogs with intermittent nonspecific signs that get better with support therapy. Presumably, hypoarenocorticism must be under diagnosed in veterinary medicine, reinforcing the need to require specific exams in patients that show this wax and wane feature of clinical signs.

scholarly journals The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism: a retrospective study of eight cases

2018 ◽  
Vol 87 (6) ◽  
pp. 309-313
Author(s):  
M. Albers ◽  
P. Defauw ◽  
F. Mortier ◽  
S. Daminet
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Small Animal ◽  
Dosing Interval ◽  
Fludrocortisone Acetate

In this article, the use of desoxycorticosterone pivalate is retrospectively reviewed in eight dogs with primary hypoadrenocorticism, presented at the Small Animal Department of Ghent University. The results showed that desoxycorticosterone pivalate provided adequate mineralocorticoid replacement in all cases, also in the dogs that had previously been treated with fludrocortisone acetate. A starting dosage of 1.5 – 2.2 mg/kg SC was used, with a fixed dosing interval of 28 days in most of the cases. Each time, prednisolone was added to the therapy as glucocorticoid supplementation. No side effects related to desoxycorticosterone pivalate therapy were noted and all owners were satisfied with the treatment consisting of desoxycorticosterone pivalate and prednisolone.

scholarly journals Management of Sodium Balance by Using Fludrocortisone Acetate in Patients with Subarachnoid Hemorrhage in the Acute Stage

1998 ◽  
Vol 26 (4) ◽  
pp. 265-269
Author(s):  
Tatsuro MORI ◽  
Tatsuro KAWAMATA ◽  
Teruyasu HIRAYAMA ◽  
Yoichi KATAYAMA
Keyword(s):  
Subarachnoid Hemorrhage ◽  
Acute Stage ◽  
Sodium Balance ◽  
Fludrocortisone Acetate
Sign in / Sign up

Export Citation Format

Share Document